Chia-Lun Chao

Chia-Lun Chao

Auto-generated profile, based on publicly available information

Chia-Lun Chao

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
CCChern-En Chiang
Chern-En Chiang
TWTzung-Dau Wang Wang
Tzung-Dau Wang Wang
KUKwo-Chang Ueng
Kwo-Chang Ueng
TLTsung-Hsien Lin
Tsung-Hsien Lin
HYHung-I Yeh
Hung-I Yeh
SLShing-Jong Lin
Shing-Jong Lin
It has been almost 5 years since the publication of the 2010 hypertension guidelines of the Taiwan Society of Cardiology (TSOC). There is new evidence regarding the management of hypertension, including randomized controlled trials, non-randomized trials, post-hoc analyses, subgroup analyses, retrospective studies, cohort studies, and registries. More recently, the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) published joint hypertension guidelines in 2013. The panel members who were appointed to the Eighth Joint National Committee (JNC) also published the 2014 JNC report. Blood pressure (BP) targets have been changed; in particular, such targets have been loosened in high risk patients. The Executive Board members of TSOC and the Taiwan Hypertension Society (THS) aimed to review updated information about the management of hypertension to publish an updated hypertension guideline in Taiwan. We recognized that hypertension is the most important risk factor for global disease burden. Management of hypertension is especially important in Asia where the prevalence rate grows faster than other parts of the world. In most countries in East Asia, stroke surpassed coronary heart disease (CHD) in causing premature death. A diagnostic algorithm was proposed, emphasizing the importance of home BP monitoring and ambulatory BP monitoring for better detection of night time hypertension, early morning hypertension, white-coat hypertension, and masked hypertension. We disagreed with the ESH/ESH joint hypertension guidelines suggestion to loosen BP targets to <140/90 mmHg for all patients. We strongly disagree with the suggestion by the 2014 JNC report to raise the BP target to <150/90 mmHg for patients between 60-80 years of age. For patients with diabetes, CHD, chronic kidney disease who have proteinuria, and those who are receiving antithrombotic therapy for stroke prevention, we propose BP targets of <130/80 mmHg in our guidelines. BP targets are <140/90 mmHg for all other patient groups, except for patients ≥80 years of age in whom a BP target of <150/90 mmHg would be optimal. For the management of hypertension, we proposed a treatment algorithm, starting with life style modification (LSM) including S-ABCDE (Sodium restriction, Alcohol limitation, Body weight reduction, Cigarette smoke cessation, Diet adaptation, and Exercise adoption). We emphasized a low-salt strategy instead of a no-salt strategy, and that excessively aggressive sodium restriction to <2.0 gram/day may be harmful. When drug therapy is considered, a strategy called "PROCEED" was suggested (Previous experience, Risk factors, Organ damage, Contraindications or unfavorable conditions, Expert's or doctor's judgment, Expenses or cost, and Delivery and compliance issue). To predict drug effects in lowering BP, we proposed the "Rule of 10" and "Rule of 5". With a standard dose of any one of the 5 major classes of anti-hypertensive agents, one can anticipate approximately a 10-mmHg decrease in systolic BP (SBP) (Rule of 10) and a 5-mmHg decrease in diastolic BP (DBP) (Rule of 5). When doses of the same drug are doubled, there is only a 2-mmHg incremental decrease in SBP and a 1-mmHg incremental decrease in DBP. Preferably, when 2 drugs with different mechanisms are to be taken together, the decrease in BP is the sum of the decrease of the individual agents (approximately 20 mmHg in SBP and 10 mmHg in DBP). Early combination therapy, especially single-pill combination (SPC), is recommended. When patient's initial treatment cannot get BP to targeted goals, we have proposed an adjustment algorithm, "AT GOALs" (Adherence, Timing of administration, Greater doses, Other classes of drugs, Alternative combination or SPC, and LSM + Laboratory tests). Treatment of hypertension in special conditions, including treatment of resistant hypertension, hypertension in women, and perioperative management of hypertension, were also mentioned. The TSOC/THS hypertension guidelines provide the most updated information available in the management of hypertension. The guidelines are not mandatory, and members of the task force fully realize that treatment of hypertension should be individualized to address each patient's circumstances. Ultimately, the decision of the physician decision remains of the utmost importance in hypertension management.

1 November 2009 in Clinica Chimica Acta
Verified
Journal Article
Closed access
YLYen-Hung Lin
Yen-Hung Lin
LLLian-Yu Lin
Lian-Yu Lin
YWYen-Wen Wu
Yen-Wen Wu
KCKuo-Liong Chien
Kuo-Liong Chien
CLChii-Ming Lee
Chii-Ming Lee
MCMing-Fong Chen
Ming-Fong Chen

8 February 2000 in Circulation
Verified
Journal Article
Closed access
PDF file
CCChia-Lun Chao
Chia-Lun Chao
TKTsung-Li Kuo
Tsung-Li Kuo
YLYuan-Teh Lee
Yuan-Teh Lee
Background —Homocysteine-mediated endothelial dysfunction has been proposed to occur via oxidative stress mechanisms in humans. However, there is controversy regarding the effects of homocysteine on endothelial function and oxidative status, which may in part result from age discrepancy across the studies. The present study was designed to investigate the aging effect on the relationship between endothelium-dependent vasodilation and oxidative status in methionine-induced hyperhomocysteinemia. Methods and Results —Plasma homocysteine, phosphatidylcholine hydroperoxide (PCOOH), P-selectin levels, and brachial artery flow-mediated vasodilation were measured at baseline and 4 hours after an oral methionine load (0.1 g/kg) in 15 younger (21 to 40 years) and 15 older (55 to 70 years) healthy adults. Homocysteine increased from 7.3±1.3 μmol/L at baseline to 22.7±5.2 μmol/L at 4 hours in younger ( P <0.001) and from 7.4±1.4 to 24.3±4.5 μmol/L in older adults ( P <0.001). PCOOH levels were not significantly different between baseline and 4 hours in both groups ( P =0.10 in young; P =0.14 in old). P-selectin, which is expected to increase during oxidative stress, was not changed in older ( P =0.08) but decreased in younger adults ( P =0.037) at 4 hours. Flow-mediated vasodilation was preserved from 13.1±2.1% at baseline to 13.5±2.8% at 4 hours in younger ( P =0.49) and decreased from 12.8±2.4% to 8.5±2.8% in older adults ( P <0.001). Conclusions —The present study demonstrates that endothelial dysfunction caused by methionine-induced hyperhomocysteinemia is age-related and is mediated through impaired nitric oxide activity without change of oxidative status. Our data do not support previous hypotheses that endothelial damage by homocysteine is via oxidative stress mechanism in humans.

1 February 2007 in JACC
Verified
Journal Article
Closed access
HKHsien-Li Kao
Hsien-Li Kao
MLMao-Shin Lin
Mao-Shin Lin
CWChia-Sung Wang
Chia-Sung Wang
YLYen-Hung Lin
Yen-Hung Lin
LLLung-Chun Lin
Lung-Chun Lin
SCShih-Chung Chen
Shih-Chung Chen

1 October 2011 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
CHChi-Lun Huang
Chi-Lun Huang
YWYen-Wen Wu
Yen-Wen Wu
CHChueh-Lung Hwang
Chueh-Lung Hwang
YJYuh-Shiun Jong
Yuh-Shiun Jong
CCChia-Lun Chao
Chia-Lun Chao
WYWei-Shiung Yang
Wei-Shiung Yang

1 October 2011 in Stroke
Verified
Journal Article
Closed access
MLMao-Shin Lin
Mao-Shin Lin
MCMing-Jang Chiu
Ming-Jang Chiu
YWYen-Wen Wu
Yen-Wen Wu
CHChing-Chang Huang
Ching-Chang Huang
CCChi-Chao Chao
Chi-Chao Chao
HKHsien-Li Kao
Hsien-Li Kao
Background and Purpose—: Chronic cerebral hypoperfusion may lead to impairment in neurocognitive performance in patients with chronic internal carotid artery occlusion, and the effects of carotid artery stenting on neurocognitive function have been unclear. Methods—: We prospectively enrolled 20 chronic internal carotid artery occlusion patients with objective ipsilateral hemisphere ischemia, in whom carotid artery stenting was attempted. Functional assessments, including the National Institutes of Health Stroke Scale, Barthel Index, and a battery of neuropsychological tests, including the Mini-Mental State Examination, Alzheimer Disease Assessment Scale–Cognitive Subtest, verbal fluency, and Color Trail Making A and B, were administered before and 3 months after intervention. Results—: Successful recanalization was achieved in 12 of 20 patients (60%). There was no procedural or new cerebral ischemic event, except for 1 intracranial hemorrhage, which occurred during the procedure and had neurologic sequelae; this case was excluded from analysis. The demographics and baseline cognitive performance were similar between the group with a successful outcome (group 1, n=12) and patients who did not (group 2, n=7). Ten of 12 patients in group 1 had improvement in ipsilateral brain perfusion after the procedure, but none in group 2 had improvement. Significant improvement in the scores on the Alzheimer Disease Assessment Scale–Cognitive Subtest (before, 7.7±8.9 versus after, 5.7±7.1; P =0.024), Mini-Mental State Examination (before, 25.8±3.8 versus after, 27.7±2.7; P =0.015), and Color Trail Making A (before, 123.2±68.6 versus after, 99.3±51.5; P =0.017) were found in group 1 but not in group 2. Conclusions—: Successful carotid artery stenting improves global cognitive function as well as attention and psychomotor processing speed in patients with chronic internal carotid artery occlusion.